ecancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France

31 May 2014

Intratumour heterogeneity in renal and lung cancer

Prof Charles Swanton - CRUK London Research Institute and UCL, London, UK

6 May 2014

Role of AORTIC in dealing with rising cancer rates in Africa

North American Vice president of AORTIC

1 May 2014

Promising advances in the treatment of lung cancer using MK-3475 as an immune checkpoint inhibitor

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

1 May 2014

Benefits found for lung cancer patients with high levels of PD-L1 with MK-3475 treatment

Dr Leena Gandhi - Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

1 May 2014

Role of genomics in assessing risk, especially in ovarian cancer

Dr Thomas Sellers - Moffitt Cancer Center, Tampa, USA

1 May 2014

The 1st Immunotherapy of Cancer Conference (ITOC)

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria

25 Mar 2014

mRNA-based cancer vaccines

Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh

24 Mar 2014

ecancermedicalscience Editor's Choice for January 2014

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

12 Feb 2014

Toxicity complications from chemotherapy in lung cancer treatment

Dr G.S. Bhattacharyya - FORTIS Hospitals, Kolkata, India

5 Dec 2013

Cancer cells and the immune system: a natural story?

Prof. Laurence Zitvogel - INSERM, Institut Gustave Roussy, Villejuif, France

3 Dec 2013

Immuno-Oncology: the next new paradigm in cancer treatment? Chairman's welcome and introduction

Prof. Winald Gerritsen - Radboud University Nijmegen Medical Centre, The Netherlands

3 Dec 2013

More from ecancer